2023 The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2023 SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria Group Severe Aplastic Anaemia Working Party (SAAWP) Infectious Diseases Working Party (IDWP) 1st listed author Morag Griffin Journal Haematologica.
2023 Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT Group Transplant Complications Working Party (TCWP) 1st listed author Lars Klingen Gjærde Journal Bone Marrow Transplant.
2023 Improved post-transplant outcomes in recent years for AML patients with FLT3-ITD and wild-type NPM1: a report from the EBMT acute leukemia working party Group Acute Leukemia Working Party (ALWP) 1st listed author Ali Bazarbachi Journal Clin Cancer Res.
2023 Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study Group Transplant Complications Working Party (TCWP) 1st listed author Tapani Ruutu Journal Bone Marrow Transplant.
2023 Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Jaime Sanz Journal Bone Marrow Transplant.
2023 Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Rémi Tilmont Journal Bone Marrow Transplant.
2023 Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group Group GoCART Coalition 1st listed author Katerina Nezvalova-Henriksen Journal Bone Marrow Transplant.
2023 Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal J Hematol Oncol.
2023 Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2023 Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Br J Haematol.
2023 Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis Group Acute Leukemia Working Party (ALWP) 1st listed author Sjoerd J F Hermans Journal Hemasphere.